Copyright
©The Author(s) 2022.
World J Transplant. Jul 18, 2022; 12(7): 184-194
Published online Jul 18, 2022. doi: 10.5500/wjt.v12.i7.184
Published online Jul 18, 2022. doi: 10.5500/wjt.v12.i7.184
Exercise group | Control group | P value | |
Sex (male/female) | 8/3 | 8/2 | 0.52 |
Age (yr) | 52.9 ± 9.5 | 53.0 ± 13.1 | 0.51 |
Height (cm) | 1.6 ± 0.5 | 1.6 ± 0.0 | 0.34 |
Weight (kg) | 70.8 ± 12.2 | 72.1 ± 6.7 | 0.77 |
BMI (kg/m2) | 24.4 ± 2.6 | 25.6 ± 2.0 | 0.23 |
Place of residence | |||
Rural area | 27.2% (3/11) | 40.0% (4/10) | 0.69 |
Urban area | 72.7% (8/11) | 60.0% (6/10) | 0.42 |
Education | |||
Primary education | 54.5% (6/11) | 40.0% (4/10) | 0.33 |
Secondary education | 18.1% (2/11) | 10.0% (1/10) | 0.68 |
Higher education | 9.0% (1/11) | 20.0% (2/10) | 0.65 |
No education | 18.1% (2/11) | 30.0% (3/10) | 0.70 |
Employment status | |||
Employed | 18.1% (2/11) | 10.0% (1/10) | 0.71 |
Unemployed | 54.5% (6/11) | 40.0% (4/10) | 0.53 |
Retired | 27.2% (3/11) | 50.0% (5/10) | 0.38 |
Smoking | 18.1% (2/11) | 10.0% (1/10) | 0.74 |
eGFR-CKD-EPI equation (mL/min) | 61.0 ± 7.3 | 59.5 ± 8.2 | 0.53 |
Stage of diabetic nephropathy | |||
Stage 3 | 81.8% (9/11) | 90.0% (9/10) | 0.77 |
Stage 4 | 18.1% (2/11) | 10.0% (1/10) | 0.64 |
Time after KTx (mo) | 47.4 ± 18.3 | 47.8 ± 18.1 | 0.68 |
Primary causes of ESKD | |||
Diabetes mellitus | 54.5% (6/11) | 50.0% (5/10) | 0.64 |
Hypertension | 27.2% (3/11) | 20.0% (2/10) | 0.56 |
Polycystic kidney disease | 18.1% (2/11) | 10.0% (1/10) | 0.56 |
Glomerulonephritis | 9.0% (1/11) | 10.0% (1/10) | 0.72 |
Nephrosclerosis | 9.0% (1/11) | 0.0% (0/10) | 0.55 |
Reflux nephropathy | 0.0% (0/11) | 10.0% (1/10) | 0.61 |
Others | 0.0% (0/11) | 10.0% (1/10) | 0.59 |
Medication | |||
Statins | 100.0% (11/11) | 100.0% (10/10) | 0.53 |
Calcium channel blockers | 36.3% (4/11) | 50.0% (5/10) | 0.23 |
Oral antidiabetic drugs | 18.1% (2/11) | 30.0% (3/10) | 0.51 |
Angiotensin II receptor blockers/angiotensin converting enzyme blockers | 54.5% (6/11) | 50.0% (5/10) | 0.66 |
Slow and/or intermediate acting insulin | 81.9% (9/11) | 70.0% (7/10) | 0.47 |
Immunosuppression therapy (corticosteroid, tacrolimus, mycophenolate mofetil) | 100.0% (11/11) | 100.0% (10/10) | 0.74 |
Adherence to medication | 90.9% (10/11) | 100.0% (10/10) | 0.82 |
Hematocrit (%) | 42.1 ± 4.6 | 39.8 ± 4.5 | 0.63 |
Hemoglobin (g/dL) | 14.1 ± 1.0 | 13.1 ± 1.6 | 0.16 |
Na+ (mg/dL) | 139.8 ± 2.5 | 140.3 ± 4.3 | 0.90 |
K+ (mg/dL) | 4.1 ± 0.3 | 4.3 ± 0.5 | 0.15 |
Ca2+ (mg/dL) | 10.1 ± 0.5 | 9.7 ± 0.9 | 0.94 |
P (mg/dL) | 2.9 ± 0.5 | 3.4 ± 0.4 | 0.09 |
Mg+ (mg/dL) | 1.6 ± 0.1 | 1.6 ± 0.3 | 0.50 |
Fe+ (mg/dL) | 89.8 ± 23.2 | 87.9 ± 16.6 | 0.54 |
Urea (mg/dL) | 42.2 ± 8.7 | 48.1 ± 16.7 | 0.90 |
Creatinine (mg/dL) | 1.1 ± 0.2 | 1.2 ± 0.5 | 0.16 |
Alkaline phosphatase (mg/dL) | 72.1 ± 27.2 | 62.5 ± 10.4 | 0.17 |
Uric acid (mg/dL) | 5.7 ± 1.1 | 5.9 ± 1.2 | 0.23 |
24-h urine albumin level (mg/dL) | 106.4 ± 25.1 | 115.6 ± 20.9 | 0.25 |
- Citation: Michou V, Nikodimopoulou M, Deligiannis A, Kouidi E. Metabolic and functional effects of exercise training in diabetic kidney transplant recipients. World J Transplant 2022; 12(7): 184-194
- URL: https://www.wjgnet.com/2220-3230/full/v12/i7/184.htm
- DOI: https://dx.doi.org/10.5500/wjt.v12.i7.184